Therapeutic Areas Precision Science Applied to the Biology of Health and Disease Supported by Peer-Reviewed Research Quanterix’ proprietary Simoa® technology is supported by over 1,000 peer-reviewed publications, covering all of our platforms and therapeutic areas. SEE ALL PUBLICATIONS Total Biomarker Assays 0 Oncology 0 Neurology 0 Immunology 0 Cardiology 0 Infectious Disease Stay Tuned Subscribe to our newsletter SUBMIT info@quanterix.com 617 301 9400 900 middlesex tpke billerica, ma 01821 usa Investor Portal Customer Portal Contact Us Terms And Conditions Privacy Shield Statement © 2021 Quanterix All rights reserved. Privacy Policy By continuing to use this website you are acknowledging and agree with our cookie policy. AGREELearn more

Neurology Simoa® is not just a better way to detect CNS biomarkers. It’s a 1,000-times better way. The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed. Simoa assays can detect neurological biomarkers, such as Neurofilament Light (NfL), Tau, GFAP and several others associated with brain injury and disease. With Simoa, these informative markers can be detected at much earlier stages, in blood, serum or plasma, enabling better understanding of the long-term effects and disease pathology without invasive measures. Quanterix has a strategic focus in neurodegeneration, neuroinflammation, traumatic brain injuries (TBI) and multiple sclerosis (MS) and is working with a rapidly growing network of academic researchers and pharmaceutical and biotech partners to drive advancements in head health research. REQUEST MORE INFORMATION Click through the alphabet to see available assays A B G I M N P R S T U ALPHA-SYNUCLEIN ALPHA2-MACROGLOBULIN Aβ40 Aβ42 Using Simoa to Indentify Blood Biomarkers for CNS Disorders Hosted by Cambridge Healthtech Institute, this webinar describes how blood biomarkers can be used to detect CNS disorders. Related Publications OCT 22, 2021 Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus READ ARTICLE OCT 22, 2021 Blood Neurofilament Light Chain as a Potential Biomarker for Central and Peripheral Nervous Toxicity in Rats READ ARTICLE OCT 18, 2021 Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum READ ARTICLE SEE ALL RELATED PUBLICATIONS Stay Tuned Subscribe to our newsletter SUBMIT info@quanterix.com 617 301 9400 900 middlesex tpke billerica, ma 01821 usa Investor Portal Customer Portal Contact Us Terms And Conditions Privacy Shield Statement © 2021 Quanterix All rights reserved. Privacy Policy By continuing to use this website you are acknowledging and agree with our cookie policy. AGREELearn more